Replimune(REPL) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update • Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus nivolumab in anti-PD1 failed melanoma via the accelerated approval pathway before the end of the year • IGNYTE-3 confirmatory trial of RP1(vusolimogene oderparepvec) in advanced melanoma underway with first patient enrolled in August • Presented la ...